Key Insights

Highlights

Treatment Research

7 treatments under study, led by Pegfilgrastim

Related Conditions

Often studied with 9 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Withdrawn1

Clinical Trials (1)

Showing 1 of 1 trials
NCT01639521Phase 2Withdrawn

Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer

Showing all 1 trials

Research Network

Common Treatments

  • Pegfilgrastim1
  • Laboratory Biomarker Analysis1
  • Doxorubicin Hydrochloride1
  • Vinblastine1
  • Cisplatin1

Active Sponsors

  • University of Southern California1
  • National Cancer Institute (NCI)1

Top Investigators

Related Conditions

  • Ureter Cancer1
  • Transitional Cell Carcinoma Of The Bladder1
  • Recurrent Bladder Cancer1
  • Anterior Urethral Cancer1
  • Stage Iii Bladder Cancer1

Activity Timeline